MedPath

Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease

Phase 1
Recruiting
Conditions
Progressive Fibrosing Interstitial Lung Diseases
Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
Registration Number
CTIS2022-502512-36-00
Lead Sponsor
Aarhus University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Patients diagnosed with IPF or fibrotic ILD who fulfills PPF criteria, and are prescribed antifibrotic treatment., Age 18-90, Cognitively able to understand and participate in the study, Pre-menopausal women must be confirmed non-pregnant by an onsite test.

Exclusion Criteria

Contraindications for MRI (Pacemaker, neurostimulator or cochlear implant; Metal foreign bodies such as fragments and irremovable piercings; Unsafe medical implants (safety of heart valves, hips and the like must be confirmed); Intrathoracic clips or coils; Cardiac pacemakers; Claustrophobia; Largest circumference including arms > 160 cm), Contraindications to gadolinium contrast (eGFR < 30 mL/min/1.73m2; Previous adverse reactions to gadolinium), Overlapping emphysematic disease where the emphysema-component outweighs the fibrosis, Unable to perform breath-hold of minimum 20 seconds., Allergy to Xenon, Breast feeding, Evidence of ongoing respiratory infections at time of MR examinations

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath